A randomized, double-blind, placebo-controlled, parallel-arm Phase III trial of tesofensine in patients with obesity

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-arm Phase III trial of tesofensine in patients with obesity

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Tesofensine (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Sponsors Medix
  • Most Recent Events

    • 01 Feb 2018 Status changed from recruiting to active, no longer recruiting, according to a Saniona media release,.
    • 01 Feb 2018 According to a Saniona media release, data form this trial will be used to submit an application of dossier in 2019 and subsequently may lead to market approval of Tesofensine in Mexico. The trial is expected to be completed in 2018 and topline data is expected by early 2019.
    • 18 Sep 2017 According to a Saniona media release, Medix, has recruited 150 out of the planned 372 patients in the study during the first six weeks. The company may achieve a completion of the study in less than the previously announced two years.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top